GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's (GSK) U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a stock buyback on the back of optimism about sales of its new drugs.
GSK plc (GSK) Q4 2024 Earnings Call Transcript
GSK plc (NYSE:GSK ) Q4 2024 Earnings Conference Call February 5, 2025 5:45 AM ET Company Participants Dame Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Julie Brown - Chief Financial Officer David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants Emily Field - Barclays Bank Richard Parkes - BNPP Exane Peter Welford - Jefferies Steve Scala - TD Cowen Rajan Sharma - Goldman Sachs Justin Smith - Bernstein Graham Parry - Bank of America James Gordon - JPMorgan Chase Operator Hello, everyone. Welcome to today's call and webcast.
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales. The post GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion appeared first on Investor's Business Daily.
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.72 per share a year ago.
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
Wednesday, GSK Plc GSK reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion.
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early trading, making it the top performer on the FTSE 100 and on track for its biggest one-day gain since 2022.
GSK shares rise 5% as it navigates vaccines woes to upgrade sales target
GSK PLC (LSE:GSK, NYSE:GSK) shares climbed 5% in early trading on Wednesday after the drugs giant appeared to shrug off vaccine-related woes and mollified the City by raising its long-term sales target. It is now expecting revenue to exceed £40 billion by 2031, up from £38 billion previously.
GSK upgrades long-term sales target; but Arexvy's struggles are confirmed
GSK PLC (LSE:GSK, NYSE:GSK) has raised its long-term revenue forecast, now expecting sales to exceed £40 billion by 2031, up from its previous £38 billion target. The upgrade comes after what the company described as a "strong" financial performance in 2024, driven by the growth of its specialty medicines portfolio.
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division.
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
